CN101850043B - Application of crex rigescens in preparation of medicament for resisting respiratory syncytial virus - Google Patents
Application of crex rigescens in preparation of medicament for resisting respiratory syncytial virus Download PDFInfo
- Publication number
- CN101850043B CN101850043B CN201010196812XA CN201010196812A CN101850043B CN 101850043 B CN101850043 B CN 101850043B CN 201010196812X A CN201010196812X A CN 201010196812XA CN 201010196812 A CN201010196812 A CN 201010196812A CN 101850043 B CN101850043 B CN 101850043B
- Authority
- CN
- China
- Prior art keywords
- rigescens
- franch
- hsv
- krecz
- var
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of crex rigescens in preparation of a medicament for resisting respiratory syncytial virus. The experiment shows that the crex rigescens has the obvious inhibition function on HSV-1, HSV-2, HCMV, RSV and flu A, which hints that the crex rigescens has the potential application value in the field of treating various virus infectious diseases, and more significant meanings on treatment of infectious diseases of herpetoviridae (HSV-1, HSV-2 and HCMV). The invention provides the experiment evidence for crex rigescens for treating the virus infectious diseases, and provides a certain guiding meaning on medicaments of resisting HSV-1, HSV-2, HCMV, RSV and Flu A, thereby having important reference value.
Description
Technical field
The present invention relates to Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) in preparation anti respiratory syncytial virus (Respiratory Syncytial Virus, the application in medicine RSV).
Background technology
Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), Cyperaceae, sedge belong to, Latin: Carex rigescens (Franch.) V.Krecz. (C.stenophyllaWahlb.var.rigescens Franch.), have another name called little cotton grass, be distributed in ground such as Liaoning, North China, Shandong, Henan, northwest in China, be common in meadow, hillside and river bank, be perennial plant, morphological characteristic: the elongated root stock of crawling of tool, stalk is high 5～40 centimetres, and base portion has the fibrous splitted old sheath of pitchy.Blade is shorter than stalk, and is wide 1～3 millimeter, flat.Spike is avette or square is circular, 5～8 in small ear, the intensive stalk end of being born in; Avette or the width egg shape of small ear, long 5～8 millimeters, top minority male flower, other all are female flower.The bract flakey, the fruit capsule is avette or oval, and is closely isometric with scale, the most arteries and veins of two masks, the base portion circle omits the tool spongy tissue, and the edge is aptery, the anxious short beak, beak mouth tool 2 little teeth, the wide ellipse of pyrene of being condensed in top.How viewing and admiring lawn or the suitable rest lawn of trampleing on as park, scenic spot, flower garden now, is the good cover plants in ground such as highway, railway both sides.
Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) does not all have record as medicinal plants at Compendium of Material Medica, " Chinese medicinal herbal ", the Pharmacopoeia of the People's Republic of China (2005 editions), and " China's book on Chinese herbal medicine " record is returned through three warmers, spleen, stomach, kidney, sweet in the mouth, hardship, puckery, property is put down, and has the treating stranguria effect of clearing away heat and promoting diuresis, cures mainly chyluria.But have not yet to see the document announcement that Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) or Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) extract have antiviral activity.
Flu A belongs to Orthomyxoviridae, at human and other biological annual among a small circle popular of all having, causes that upper respiratory system infects.When being very popular, can cause serious respiratory system infection, very the person causes pneumonia, encephalitis even death;
HCMV, HSV-1, HSV-2 belong to the herpes coe virus, HCMV causes the beneath crowd's of immunity severe infections, intrauterine infection causes miscarriage, premature labor, stillborn fetus and deformity, and neonatal jaundice, hepatitis, pneumonia etc. also are simultaneously one of human atherosclerotic important cause of diseases; HSV-1 and HSV-2 not only cause lip or reproduction herpes mucosae, also are the important cause of diseases that causes encephalitis, hepatitis, whole body severe infections even intrauterine infection simultaneously;
RSV mainly causes respiratory system infection, causes serious pneumonia infant, old age and immunodeficiency crowd, is one of important cause of disease of human upper respiratory tract infection.
Summary of the invention
At above-mentioned prior art, the invention provides the new purposes of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) in pharmacy:
The application of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) in the medicine of the anti-HSV-1 of preparation.
The application of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) in the medicine of the anti-HSV-2 of preparation.
The application of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) in the medicine of the anti-HCMV of preparation.
The application of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) in the medicine of the anti-Flu A of preparation.
The application of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) in the medicine of the anti-RSV of preparation.
The application of described Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) is specially: earlier Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) is carried out pre-treatment, the extract that pre-treatment is obtained is used to prepare antiviral drug then, as extract being made capsule, tablet, granule, oral liquid formulations etc. with medically acceptable adjuvant, extract is further purified also can makes ejection preparation.
Described pre-treatment is one of following six kinds of modes:
1. the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) aquatic foods are squeezed the juice: get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), physical method is squeezed the juice, and obtains extract.
2. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) water extract: get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), add distilled water and boil, filter and obtain liquor, be water extract.
3. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) acetone extract: get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), through water/acetone extraction, rotary evaporation gets paste, is acetone extract, it is dissolved in be ready for use on test in the cell maintenance medium.
4. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) alcohol extract: get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), extract through water/methanol (or ethanol), rotary evaporation gets paste, is alcohol extract, it is dissolved in be ready for use on test in the cell maintenance medium.
5. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) ethyl acetate extract: acetone extract with petroleum ether, chloroform collection, the extracting of ethyl acetate branch, is ethyl acetate extract, it is dissolved in is ready for use on test in the cell maintenance medium.
6. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) silicagel column separation component: the ethyl acetate extract in will be 5. separates with silicagel column, use the chloroform/methanol gradient elution, 6: 4,5: 5,4: 6 elution fractions collecting chloroform/methanol are the post separation component, it are dissolved in be ready for use on test in the cell maintenance medium.
The experiment proved that the above-mentioned different extracts of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) all have significant inhibitory effect to HSV-1, HSV-2, HCMV, RSV and flu A:
A. the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) aquatic foods are squeezed the juice: suppress HSV 1, HSV 2, RSV the HEK293 cell occur the CPE effect (CytopathicEffect, CPE), IC
50Be respectively 2
-11.96, 2
-10.56.With 2
-10.50, TI is respectively 895.78,522.76 and 274.37; Suppress HCMVAD
169CPE, IC take place at HEL
50Be 2
-10.47, TI is 512; Suppress Flu A and at MDCK CPE takes place, IC
50Be 2
-7.58, TI is 73.52.
B. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) water extract: suppress HSV 1, HSV 2, RSV at HEK293 CPE take place, IC
50Be respectively 2
-4.50, 2
-4.46.With 2
-3.76, TI is respectively 6.45 and 6.92 and 2.20; Suppress HCMV AD
169CPE, IC take place at HEL
50Be 2
-5.38, TI is 12.91; Suppress Flu A and at MDCK CPE takes place, IC
50Be 2
-4.39, TI is 6.36.
C. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) acetone extract: suppress HSV 1, HSV 2 and RSV and at HEK293 CPE takes place, IC
50Be respectively 2
-10.51, 2
-9.60With 2
-9.94, TI is respectively 247.28,130.60 and 166.57; Suppress HCMV AD
169CPE, IC take place at HEL
50Be 2
-8.61, TI is 73.01; Suppress Flu A and at MDCK CPE takes place, IC
50Be 2
-7.88, TI is 42.52.
D. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) alcohol extract: suppress HSV 1, HSV 2 and RSV and at HEK293 CPE takes place, IC
50Be respectively 2
-9.94, 2
-8.63With 2
-8.54, TI is respectively 176.07,71.01 and 66.72; Suppress HCMV AD
169At HEL, IC
50Be 2
-8.38, TI is 64.89; Suppress Flu A and at MDCK CPE takes place, IC
50Be 2
-854, TI is 70.52.
E. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) ethyl acetate extract: suppress HSV 1, HSV 2 and RSV and at HEK293 CPE takes place, IC
50Be respectively 2
-11.44, 2
-10.09With 2
-9.54, TI is respectively 451.93,177.29 and 121.09; Suppress HCMV AD
169CPE, IC take place at HEL
50Be 2
-10.40, TI is 213.78; Suppress Flu A and at MDCK CPE takes place, IC
50Be 2
-8.54TI is 60.55.
F. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) silicagel column separation component: suppress HSV 1, HSV 2 and RSV and at HEK293 CPE takes place, IC
50Be respectively 2
-9.52, 2
-9.54With 2
-9.56, TI is respectively＞367.09,＞372.22 and＞＞377.41; Suppress HCMV AD
169CPE, IC take place at HEL
50Be 2
-9.27, TI is＞308.69; Suppress Flu A and at MDCK CPE takes place, IC
50Be 2
-4.40, TI is＞10.56.
For ease of observing and comparing, foregoing sees table 1 for details.
Table 1 Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) toxin inhibitory test result (IC
50/ TI)
As can be seen from the above table, each extract of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) has significant inhibitory effect to multiple virus, this prompting Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) is inducing diuresis for treating stranguria syndrome, treatment chyluria (China's book on Chinese herbal medicine record) not only, and have potential using value in treatment multiple disease of viral infection field, particularly great to the treatment meaning of herpes coe virus (HSV-1, HSV-2, HCMV) infectious disease.The present invention is used for the treatment of disease of viral infection for Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) is clinical provides experimental basis, provides certain directive significance to the medicine of developing anti-HSV-1, HSV-2, HCMV, RSV and Flu A virus, has important value.
In order to understand essence of the present invention better, the present invention is further illustrated below in conjunction with embodiment.
Description of drawings
Fig. 1 is the HSV-1 virus control: complete CPE sketch map (200 *) appears in the HEK293 cell;
Fig. 2 is the HSV-2 virus control: complete CPE sketch map appears in the HEK293 cell; (200 *);
Fig. 3 is the HCMV virus control: the CPE sketch map appears in hel cell; (200 *);
Fig. 4 is the RSV virus control: 90% above CPE sketch map (200 *) appears in the HEK293 cell;
Fig. 5 is that 90% above CPE sketch map (200 *) appears in Flu-A virus control: MDCK;
Fig. 6 is the HEK293 cell sketch map (200 *) that is protected;
Fig. 7 is the hel cell sketch map (200 *) that is protected.
Fig. 8 is the mdck cell sketch map (200 *) that is protected;
The specific embodiment
Embodiment: the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) extract is studied the effect of virus:
(1) preparation Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) extract:
Get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) adopt physical method to squeeze the juice respectively (fresh grass is squeezed the juice), decocting in water, water/acetone extraction, water/ethanol extraction obtain respectively that 1. aquatic foods squeeze the juice, water extract 2., acetone extract 3. with alcohol extract 4., to 3. or 4. use petroleum ether, chloroform, the extracting of ethyl acetate branch, getting ethyl acetate extraction part 5. is, to 5. separate with silicagel column, use the chloroform/methanol gradient elution, 6: 4,5: 5,4: 6 elution fractions collecting chloroform/methanol are for 6..Be dissolved in the cell maintenance medium (MEM that contains 2% new-born calf serum, GIBICO company product) the said extracted thing standby respectively.
(2) cell strain and Strain:
HEKC (HEK293 is HSV 1, HSV 2, RSV virus sensitive cells) is available from U.S. Clontech company; Human embryonic lung cell P12 (HEL P12, HCMV sensitive strain) is given by Basic Medical Science Inst., Shandong Prov. Academy of Medical Science microbiological research chamber; Madin-Darby canine kidney(cell line) (MDCK) (MDCK, influenza virus sensitive cells) is drawn from Chinese CDC virosis institute; Herpes simplex virus type 1 (HSV-1) Sm44 strain, herpes simplex virus type 2 (HSV-1) 333 strains, respiratory syncytial virus (RSV) Long strain, the local strain of influenza virus A type (Flu A) 1995.AII:32094 and Coxsackie virus 3 types (Cox-B3) Nancy strain are drawn from Chinese CDC virosis institute, human cytomegalic inclusion disease virus AD
169Strain (HCMV AD
169), draw from the Chinese biological goods and identify institute vaccine three Room.
(3) cytotoxic assay:
Reference literature Wang passed, and Wang Lin is old superfine, and oral liquid for clearing away lung-heat pastille serum is to the inhibiting experimentation of respiratory syncytial virus, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25～27 method, each sample is done serial dilution (2 with 2 multiple proportions
-1～-5), be inoculated on MDCK, the HEL and HEK293 in 96 plate holes by the dilution sequential lateral then, every hole 100 μ L, every dilution factor vertically repeats 3 holes (A, B, C capable), parallel 1～6 hole of establishing microwell plate D is the cell contrast, 7～12 holes not inoculating cell are blank, microscopically is observed CPE every day, observe 7d continuously, dimethyl diaminophenazine chloride dyeing, measure the OD value at the 540nm wavelength, experimental group is compared the calculating cell survival rate with cell matched group OD value, calculate medicine half cytotoxic concentration (TD with the Reed-Muench method
50).
(4) toxin inhibitory test:
Reference literature Wang passed, and Wang Lin is old superfine, and oral liquid for clearing away lung-heat pastille serum is to the inhibiting experimentation of respiratory syncytial virus, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25～27 method, sample is inoculated on the cell monolayer in 96 plate holes by the dilution sequential lateral, every hole 100 μ L, every dilution factor vertically repeat 4 holes, and the A of microwell plate, B, C capable adding, contained 100 TCID
50Virus 100 μ L as test group, D is capable, and the capacity cell maintenance medium that replenish to wait is the contrast of variable concentrations medicine, the parallel F that establishes is capable of virus control, what E was capable 1～12 contrasts as cell.Totally 6 samples and 6 viral test group, 6 samples include RSV-HEK293, HSV 1-HEK293, HSV 2-HEK293, Flu A-MDCK, HCMV-HEL and Cox B3-HEK293 Infection in Vitro model, 37 ℃, 5%CO
2Cultivate, observe CPE every day, observe 4d continuously.When 90% above CPE appears in virus control, add the dyeing of 1% dimethyl diaminophenazine chloride, read the A value with microplate reader at wavelength 540nm wavelength, each is organized the A value and removes virus control group A value, each test group is compared with cell control group A value, obtain cell survival rate, calculate half with the Reed-Muench method and press down malicious concentration (IC
50), TD the most at last
50And IC
50Compare and obtain to press down malicious index (TI).
(5) result:
1. sample TD
50Mensuration: the cellular control unit microscopically is observed the adherent growth densification, form is good.Squeeze the juice, the TD of water extract, acetone extraction, alcohol extract and acetic acid ethyl ester extract
50Be respectively 2 at MDCK
-1.38, 2
-1.72, 2
-2.47, 2
-2.48With 2
-2.56Be respectively 2 at HEL
-1.47, 2
-1.69, 2
-2.42, 2
-2.36With 2
-2.66, be respectively 2 at HEK293
-1.53, 2
-1.81, 2
-2.56, 2
-2.4With 2
-2.62, and the silicagel column separated component does not all record cytotoxicity at the greatest dilution (1: 2) of each cell, i.e. TD
50＜2
-1, see table 2, table 3 and table 4 for details.
Table 2 Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) is squeezed the juice, water extract and acetone extract cell toxicity test result
Table 3 Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) alcohol extract, ethyl acetate extract and silica gel column chromatography composition cell toxicity test result
Can table 4 by table 2 and table 3:
Each extract cell toxicity test result (TD of table 4 Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.)
50)
2. press down the poison experiment: the adherent densification of cellular control unit, form are good.Mirror is observed down and is found HSV 1, HSV 2, HCMVAD
169, RSV, Flu A, Cox B3 virus control group the CPE more than 90% occurs at 3d, 3d, 10d, 2d, 4d, 2d respectively, HSV 1 and HSV 2 HEK293CPE then with swelling, many cells merge (HSV 1 causes that a plurality of cells are warm to become bulla, and HSV 2 cause be fused to vesicle), become circle, coming off is principal character (as shown in Figure 1, 2); HCMV AD
L69The CPE that occurs at HEL then with cellular swelling, the circle that expands, finally to come off be feature (as shown in Figure 3); RSV strengthens, becomes and justify, come off, be broken for principal character (as shown in Figure 4) with refractivity at HEK293CPE; Flu A MDCK CPE with refractivity strengthen, downright bad, be broken for principal character (as shown in Figure 5); Coxsackie virus then strengthens, becomes circle, broken and come off based on the cell refractivity at HEK293.
And toxin inhibitory test is respectively organized cell, and according to the diluted sample gradient, CPE appears in the gradient rule:
The a aquatic foods test group of squeezing the juice: HSV 1-HEK293 before the 10th dilution factor, HSV 2-HEK293 group before the 9th dilution factor, HCMV AD
169-HEL group before 9 holes, RSV-HEK293 test group cell before the 9th dilution factor, FluA-MDCK group cell before the 6th dilution factor, cell is protected fully (shown in Fig. 6,7,8; the fine and close adherent growth of cell); occur CPE afterwards, CPE reduces to increase the weight of gradually with sample concentration.CPE all appears in all test holes of Ke Saji B3-HEK293;
The b water extract: HSV 1-HEK293 before the 3rd dilution factor, HSV 2-HEK293 group before the 3rd dilution factor, HCMV AD
169-HEL group before 4 holes, RSV-HEK293 test group cell before the 2nd dilution factor, Flu A-MDCK group cell cell before the 3rd dilution factor is protected fully, occurs CPE afterwards, CPE reduces to increase the weight of gradually with sample concentration.CPE all appears in all test holes of Ke Saji B3-HEK293;
The c acetone extract: HSV 1-HEK293 before the 9th dilution factor, HSV 2-HEK293 group before the 8th dilution factor, HCMV AD
169-HEL group before 7 holes, RSV-HEK293 test group cell before the 8th dilution factor, Flu A-MDCK group cell cell before the 6th dilution factor is protected fully, occurs CPE afterwards, CPE reduces to increase the weight of gradually with sample concentration.CPE all appears in all test holes of Ke Saji B3-HEK293;
The d alcohol extract: HSV 1-HEK293 before the 8th dilution factor, HSV 2-HEK293 group before the 7th dilution factor, HCMV AD
169-HEL group before 7 holes, RSV-HEK293 test group cell before the 7th dilution factor, Flu A-MDCK group cell cell before the 6th dilution factor is protected fully, occurs CPE afterwards, CPE reduces to increase the weight of gradually with sample concentration.CPE all appears in all test holes of Ke Saji B3-HEK293;
The e acetic acid ethyl ester extract: HSV 1-HEK293 before the 10th dilution factor, HSV 2-HEK293 group before the 9th dilution factor, HCMV AD
169-HEL group before 9 holes, RSV-HEK293 test group cell before the 8th dilution factor, FluA-MDCK group cell cell before the 7th dilution factor is protected fully, occurs CPE afterwards, CPE reduces to increase the weight of gradually with sample concentration.CPE all appears in all test holes of Ke Saji B3-HEK293;
F silicagel column separation component: HSV 1-HEK293 before the 8th dilution factor, HSV 2-HEK293 group before the 7th dilution factor, HCMV AD
169-HEL group before 6 holes, RSV-HEK293 test group cell before the 8th dilution factor, FluA-MDCK group cell cell before the 3rd dilution factor is protected fully, occurs CPE afterwards, CPE reduces to increase the weight of gradually with sample concentration.CPE all appears in all test holes of Ke Saji B3-HEK293;
Above-mentioned brassboard is dyeed, surveys 450nmA value with microplate reader with 1% dimethyl diaminophenazine chloride, and after each was organized the A value and cuts virus control group A value, each experimental group A value was compared acquisition IC with cell control group A value
50, IC
50With TD
50Compare and obtain TI:
The a aquatic foods test group of squeezing the juice: suppress HSV 1, HSV 2, RSV at the HEK293 cell CPE, IC take place
50Be respectively 2
-11.96, 2
-10.56.With 2
-10.50, TI is respectively 895.78,522.7 and 274.37; Suppress HCMV AD
169CPE, IC take place at hel cell
50Be 2
-10.47, TI is 512; Suppress Flu A and at mdck cell CPE takes place, IC
50Be 2
-7.58, TI is 73.52.CPE all appears in all test holes of CoxB3-HEK293, shows that Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) squeezes the juice to Cox B3 unrestraint effect.
B water extract: suppress HSV 1, HSV 2 and RSV and CPE, IC take place at the HEK293 cell
50Be respectively 2
-4.50, 2
-4.46With 2
-3.76, TI is respectively 6.45,6.92 and 2.20; Suppress HCMV AD
169CPE, IC take place at hel cell
50Be 2
-5.38, TI is 12.91; Suppress Flu A and at mdck cell CPE takes place, IC
50Be 2
-4.39, TI is 6.36.CPE all appears in all test holes of CoxB3-HEK293, shows that the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) water extract is to Cox B3 unrestraint effect.
C acetone extract: suppress HSV 1, HSV 2 and RSV and CPE, IC take place at the HEK293 cell
50Be respectively 2
-10.51, 2
-9.60With 2
-9.94, TI is respectively 247.28,130.60 and 166.57; Suppress HCMV AD
169CPE, IC take place at hel cell
50Be 2
-861, TI is 73.01; Suppress Flu A and at mdck cell CPE takes place, IC
50Be 2
-7.88, TI is 42.52.CPE all appears in all test holes of CoxB3-HEK293, shows that the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) acetone extract is to Cox B3 unrestraint effect.
D alcohol extract: suppress HSV 1, HSV 2, RSV at HEK293 cell generation CPE, IC
50Be respectively 2
-9.94, 2
-8.63With 2
-8.54, TI is respectively 176.07,71.01 and 66.72; Suppress HCMV AD
169CPE, IC take place at hel cell
50Be 2
-8.38, TI is 64.89; Suppress Flu A and at mdck cell CPE takes place, IC
50Be 2
-854, TI is 70.52.CPE all appears in all test holes of CoxB3-HEK293, shows that the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) alcohol extract is to Cox B3 unrestraint effect.
E acetic acid ethyl ester extract: suppress HSV 1, HSV 2 and RSV and CPE, IC take place at the HEK293 cell
50Be respectively 2
-11.44, 2
-10.09With 2
-9.54, TI is 451.93,177.29 and 121.09; Suppress HCMV AD
169CPE, IC take place at hel cell
50Be 2
-10.40, TI is 213.78; Suppress Flu A and at mdck cell CPE takes place, IC
50Be 2
-8.54, TI is 60.55.CPE all appears in all test holes of CoxB3-HEK293, shows that the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) acetic acid ethyl ester extract is to Cox B3 unrestraint effect.
F silicagel column separator: suppress HSV 1, HSV 2 and RSV and CPE, IC take place at the HEK293 cell
50Be respectively 2
-9.52, 2
-9.54With 2
-956TI is respectively＞367.09,＞372.22 Hes,＞377.41; Suppress HCMV AD
169At the generation CPE of hel cell, IC
50Be 2
-9.27, TI is＞308.69; Suppress Flu A and at mdck cell CPE takes place, IC
50Be 2
-4.40, TI is 10.56.CPE all appears in all test holes of Cox B3-HEK293, shows that Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) silicagel column extract is to Cox B3 unrestraint effect.
Above result sees table 5, table 6 and table 7 for details.
Table 5 Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) is squeezed the juice, 7k extract and acetone extract toxin inhibitory test result
Table 6 Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) alcohol extract, ethyl acetate extract and silica gel column chromatography composition toxin inhibitory test result
Must table 7 by table 5 and Biao Ke:
Each extract toxin inhibitory test result (IC of table 7 Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.)
50/ TI)
From above experimental result as can be seen, Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) has the effect of significant herpes coe virus (comprising HSV-1HEV-2HCMV), anti-secondary sticking coe virus RSV and anti-Orthomyxoviridae flu-A, but invalid to enterovirus cox-B virus.
Claims (1)
1. the application of Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) extract in the medicine of preparation anti respiratory syncytial virus, wherein, described Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) extract prepares one of by the following method:
1. the Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) aquatic foods are squeezed the juice: get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), physical method is squeezed the juice, and obtains extract;
2. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) water extract: get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), add distilled water and boil, filter and obtain liquor, be water extract;
3. Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.) acetone extract: get Carex rigescens (Franch.) V.Krecz. (C.stenophylla Wahlb.var.rigescens Franch.), through water/acetone extraction, rotary evaporation gets paste, is acetone extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010196812XA CN101850043B (en) | 2008-07-31 | 2008-07-31 | Application of crex rigescens in preparation of medicament for resisting respiratory syncytial virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010196812XA CN101850043B (en) | 2008-07-31 | 2008-07-31 | Application of crex rigescens in preparation of medicament for resisting respiratory syncytial virus |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101386795A Division CN101327282B (en) | 2008-07-31 | 2008-07-31 | Use of Carex rigescens in preparing antivirus medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101850043A CN101850043A (en) | 2010-10-06 |
| CN101850043B true CN101850043B (en) | 2011-11-09 |
Family
ID=42801833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010196812XA Expired - Fee Related CN101850043B (en) | 2008-07-31 | 2008-07-31 | Application of crex rigescens in preparation of medicament for resisting respiratory syncytial virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101850043B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112138000B (en) * | 2020-10-09 | 2023-01-24 | 孟红 | Application of Kobophenol B in preparation of antiviral drugs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101176765A (en) * | 2007-01-16 | 2008-05-14 | 张文武 | Chinese medicine detoxication preparations and preparation method thereof |
-
2008
- 2008-07-31 CN CN201010196812XA patent/CN101850043B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101176765A (en) * | 2007-01-16 | 2008-05-14 | 张文武 | Chinese medicine detoxication preparations and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 倪培忠等.白颖苔草片剂（颗粒剂）的研制.《时珍国医国药》.2004,第15卷(第4期),223-224. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101850043A (en) | 2010-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114053343B (en) | Traditional Chinese medicine composition, preparation method and application | |
| CN102688332B (en) | A kind of Chinese medicine composition for the treatment of flu and preparation method thereof | |
| CN103622867A (en) | Method for preparing mosquito-repellent perfume containing natural plant essential oil | |
| CN101322810B (en) | Chinese traditional medicine composition for treating diabetes respiratory tract infection | |
| CN101773527A (en) | Pinecone extractive of Yunnan Pinus and preparation method and medicinal application thereof | |
| CN101327282B (en) | Use of Carex rigescens in preparing antivirus medicament | |
| CN102526573A (en) | Medicament for treating child cold | |
| CN101850043B (en) | Application of crex rigescens in preparation of medicament for resisting respiratory syncytial virus | |
| CN101837086B (en) | Application of carex rigescens in preparation of antiviral drug | |
| CN106309470B (en) | Application of sargassum fusiforme polysaccharide | |
| CN103071058A (en) | Dendrobe extract and application of dendrobe extract | |
| CN100586454C (en) | Chinese medicine composition for birds, preparing method and application of the same | |
| CN102895326A (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
| CN102764294B (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN105726920A (en) | Anti-PM2.5 chewable tablets and preparing method thereof | |
| CN102697800B (en) | Herba stellariae mediae polysaccharide composition and the application in preparation antiviral drugs thereof | |
| CN103655544A (en) | Application of jaceosidin in preparation of drugs used for preventing or treating chronic liver injury and hepatic fibrosis | |
| CN103356728A (en) | Pharmaceutical composition, preparation method thereof, preparations thereof and application thereof | |
| CN102361644A (en) | Anti dengue activity of cissampelos pareira extracts | |
| CN101543523B (en) | Uyghur drug compound recipe extracting technology for chiccory | |
| CN101485649B (en) | Application of Cajanus cajan stilbene acid and pinostrobin in Cajanus cajan leaf in preparing anti-herpesvirus medicament | |
| CN101152202B (en) | Pharmaceutical composition for treating apparatus respiratorius disease and method for preparing the same | |
| CN1218733C (en) | Medicine for treating common cold and preparation method | |
| CN106924448A (en) | Treat pharmaceutical composition of anemopyretic cold and preparation method thereof | |
| CN108902570A (en) | A kind of preventing cold, antiviral integration of drinking and medicinal herbs beverage and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG LONG Free format text: FORMER OWNER: GAO CHUAN Effective date: 20140208 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250000 JINAN, SHANDONG PROVINCE TO: 250100 JINAN, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140208 Address after: Feng Ming Shan Licheng District 250100 of Shandong Province, Ji'nan City No. 3 Building 1 unit 301 Patentee after: Zhang Long Address before: 250000, Room 201, East Building, building 5, 18 Shanxi Road, swallow Road, Lixia District, Shandong, Ji'nan Patentee before: Gao Chuan |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111109 Termination date: 20170731 |